RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.[1][2][3][4] It reached phase 1 clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed by Hoffmann-La Roche.[1][2][4]

RG-7351
Clinical data
Other namesRG7351
Drug classTrace amine-associated receptor 1 (TAAR1) partial agonist

See also

edit

References

edit
  1. ^ a b c d "RG 7351". AdisInsight. Springer Nature Switzerland AG. 5 November 2023. Retrieved 20 October 2024.
  2. ^ a b c "Delving into the Latest Updates on RG-7351 with Synapse". Synapse. 19 September 2024. Retrieved 20 October 2024.
  3. ^ Liu JF, Li JX (2018). "TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg". Frontiers in Pharmacology. 9: 279. doi:10.3389/fphar.2018.00279. PMC 5881156. PMID 29636691.
  4. ^ a b c Wu R, Liu J, Li JX (2022). "Trace amine-associated receptor 1 and drug abuse". Behavioral Pharmacology of Drug Abuse: Current Status. Adv Pharmacol. Vol. 93. pp. 373–401. doi:10.1016/bs.apha.2021.10.005. ISBN 978-0-323-91526-7. PMC 9826737. PMID 35341572.